Home
Passage Bio

Passage Bio Market Share Analysis for May 2026

Looking to get in touch? Find contact information for departments or submit a general inquiry.

Health > Biotechnology and Pharmaceuticals

Domainpassagebio.com

Year Founded2017

Employees51 - 200

Annual Revenue$25M - $50M

Passage Bio

Passage Bio (including company regionals)

passagebio.com

See more website traffic and engagement information

Passage Bio Revenue up to May 2026 is 25M - 50M

revenue generated by Passage Bio top domains

Passage Bio top domains revenue over 3 years

Revenue for Passage Bio top domains

passagebio.com25M - 50M

See more with Sales Intelligence

Total visits to Passage Bio's top domains

Understand Passage Bio market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

passagebio.com6.4K

See more with Sales Intelligence

Avg. visit duration in Passage Bio's top domains

Analyze Passage Bio engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

passagebio.com00:00:41

See more with Sales Intelligence

Avg. pageviews on Passage Bio's top domains

See how Passage Bio keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

passagebio.com1.68

See more with Sales Intelligence

Passage Bio top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Passage Bio

These are the website technologies, by industry, used by Passage Bio top domains

Advertising (5)

Facebook Custom Audiences

Widget (4)

reCAPTCHA

Conversion & Analytics (3)

Google Analytics

Social (3)

Facebook Connect

More Technologies

5

See all

News & Signals from Passage Bio

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

Newsremixtx.com merged with Passage Bio, Inc. on Jun 25th '26.Remix Therapeutics to merge with Passage Bio.

NewsPassage Bio, Inc. is developing gene therapies for central nervous system disorders.Passage Bio is developing gene therapies for central nervous system disorders.

NewsPassage Bio, Inc. attended event Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Nov 5th '25.PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) - Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will participate in a fireside chat during the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 9:30 a.m. ET in Boston, MA.